Monte Rosa Therapeutics Inc is a biopharmaceutical company engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It utilizes its Quantitative and Engineered Elimination of Neosubstrates (QuEEN), platform to design novel MGDs focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways across clinical indications in oncology and non-oncology, including immunology, inflammation, neurological and genetic diseases.